2^nd International Conference on Neuro Pharmaceutics October 10-11, 2017 London, UK

OMICS International Conferences invites all the participants from all over the world to attend 'International Conference on Neuro pharmaceutics  ' during Nov 26-28, 2017 in Dubai, UAE which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Neuropharmaceutics 2017 is the learning of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behavior. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more. OMICS International organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1: Neuro Immune Pharmacology

It deals with a branch of immunology concerned with the interactions between immunological and nervous system functions also associated autoimmune diseases.  Cortical system involves the study of mapping neural systems associated in the processing of emotion, and it focuses on the cortical components of the process of recognizing facial expressions. Encephalitis is acute inflammation of the brain resulting from a viral infection or an autoimmune disease. Transverse myelitis is a pathogenetically heterogeneous inflammatory disorder in which spinal cord is affected.  Huntington disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability.

Blood brain barrier is a selectively permeable membrane that separates the blood in the brain from other extracellular fluids. Meningitis, epilepsy, cerebral edema, multiple sclerosis etc. are various diseases associated with it. The children of age group 1 to 14 are more prone to cancer, out of which 18% is the case of brain tumour. In the first three decades of life, central nervous system has emerged as one of the three vulnerable leading sites for cancer mortality. Cerebral lymphoma is the most rapidly increasing brain tumour. 

Related Conferences: 2nd International Congress on Neuroimmunology and Therapeutics March 31-April 02 2016, USA; 5th World Congress on Pharmacology, August 08-10 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European NeurologyCongress September 10-12, 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA;Schizophrenia International Research Society Conference, April 2-6 2016, Italy 

Track 2: Molecular Neuropharmacology

Molecular neuropharmacology involves the study of neurons and agonist, Competitive antagonist and Non-competitive antagonist, receptors on neurons for developing new drugs that will treat neurological disorders of neurodegenerative diseases. Neurogenesis and repair refers to the growth and development of neuron. Neurons never function in isolation; they are organized into ensembles or circuits that process kinds of information which are referred as neuronal circuits. The GABA inhibitory neurotransmitter and serotonin neurotransmitter present in the central nervous system of mature vertebrate interacts with GABA receptor and 5HT receptor respectively. GABAA receptors are modulated by the channel of 5HT receptors through activation of various proteins. There are about 14 5HT receptor subtypes identified from last 20 years which are now researched for their significance in various disorders and treatments. Synaptopathy is a progressively popular term used to define main features of neurodegenerative and psychiatric disease. It infers that brain diseases are resulted from disruption of synaptic structure and function.

Related Conferences: Pediatric Neurology-2016, October 10-12 2016, Spain; 3rd World Congress onPharmacology, August 08-10 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for NeuroscienceAnnual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy 

Track 3: Clinical Neuropharmacology

It is the science that studies the features, properties, responses and uses of drugs mainly their therapeutic effect in humans along with toxicology, pharmacodynamics and pharmacokinetics. It also includes drug abuse, pain and hypothalamic releasing factors. 

Related Conferences: Pediatric Neurology 2016, October 10-12 2016, Spain; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy 

Track 4: Psychopharmacology

Psychopharmacology is the learning of the effects of medication on the psyche (psychology), observing changed behaviors and how molecular events are manifest in a measurable behavioral form. Neurogenesis and repair deal with other aspects on the indications for medications prescribed to address psychiatric and behavioral problems, that are associated with, including antipsychotic, anxiolytic and anticonvulsant medications, acquiredbrain injury and psychopharmacology drugs and their interaction with neurotransmitters also include mood stabilizers and treatments prescribed for disorders of attention. The treatments may cause side effects such as induction of the metabolic syndrome, type II diabetes related to the medications prescribed for management of psychiatric and behavioural disorders and disturbances. The effectiveness of the drugs can be increased by prescriber’s knowledge over emotional and interpersonal issues of the patient i.e. psychology of psychopharmacology. Schizophrenia is such a disorder which affects the thinking and acting ability of a person caused by viral infection, genetically or by immune disorder.   

Related Conferences: 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5thWorld Congress on Neurology and Therapeutics, March 14-16 2016, UK; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna ;Schizophrenia International Research Society Conference, April 2-6 2016, Italy; 47th Annual Autism Society National Conference, July 13-16 2016, USA

Track 5: Neurochemical Transmission and its Associated Interactions

Neurochemistry is the specific study of neurochemicals, including neurotransmitters and other molecules that include psychopharmaceuticals, neuropeptides, or gastrotransmitters that influence the function of neurons. It also deals how these neurochemicals influence the network of neural operation. The studies include micro-macro connection between the analysis of organic compounds active in the nervous system and neural processes such as cortical plasticity, neurogenesis and neural differentiation, synapses, autism and intellectual disability, interneuronal coordination, interaction of drugs and its effect on summation and cotransmission process and advances in astrocyte-neuron interactions in health. Astrocyte dysfunction results into neurodegenerative disease, stroke, epilepsy, migraine,  and neuroinflammatory diseases.

Related Conferences: 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5thWorld Congress on Neurology and Therapeutics, March 14-16 2016, UK; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 12-16 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy; 47th Annual Autism Society National Conference, July 13-16 2016, USA

Track 6: Behavioral Neuropharmacology

It is the study of drug dependence and how drug addiction affects the human mind, Anxiety and Autism, Measuring neural activity in Drug abuse, Alcoholism- tolerance to and physical dependence, and properties are mediated through its effects on dopamine neurons in the mesolimbic reward pathway, which connects the ventral tegmental area to the nucleus accumbens, Post-traumatic stress disorder and borderline personality disorder, clinical depression and enhanced treatments.

Related Conferences: Pediatric Neurology 2016, October 10-12 2016, Spain; 5th World Congress onNeurology and Therapeutics, March 14-16 2016, UK; 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; European NeurologyCongress September 10-12 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; ECNP 2016, 29th European College ofNeuropsychopharmacology Congress, September 17-20 2016, Vienna ; Schizophrenia International Research Society Conference, April 2-6 2016, Italy; 47th Annual Autism Society National Conference, July 13-16 2016, USA

Track 7: Chemical Neurotrasmitters

These are the brain chemicals that connect brain and the body.  They transmit signals between nerve cells, called neurons. They can also affect mood, sleep, concentration, weight, and can cause adverse symptoms when they are out of balance. These are of two types: Inhibitory and Excitatory. Acetylcholine, Glutamine and GABA are some of these neurotransmitters.

Related Conferences: 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5th World Congress on Neurology and Therapeutics, March 14-16 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy; 47th Annual Autism Society National Conference, July 13-16 2016, USA.

Track 8: Neurotechnology and its Advances

It is the measurement and analysis of chemical and electrical signals of nervous system. It includes neurocircuitary analysis, novel trans-synaptic tracing approaches, advancements of optical techniques, neuromodulation and transcranial magnetic stimulation. Neurotechnology plays a crucial role indiagnostics and identification of nervous activities.

Related Conferences: 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5th World Congress on Neurology andTherapeutics, March 14-16 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016, Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy; 47th Annual Autism Society National Conference, July 13-16 2016, USA.

Track 9: Neuroendocrinology

It is the study of interactions between the nervous system and the endocrine system, also biological features of the cells involved and their communications. Most Important aspects of neuroendocrinology are insulin receptor and hypothalamic programming; stress, coping and interactions, neuro-endocrine-immune symphony, pituitary structure and hormone secretion.

Related Conferences: Pediatric Neurology-2016, October 10-12 2016, Spain; 3rd World Congress onPharmacology, August 08-10 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Society for NeuroscienceAnnual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy. 

Track 10: Alzheimer's Disease and Dementia

Alzheimer's is a type of dementia that causes problems with memory, thinking and behaviour. Symptoms usually develop slowly and become severe enough to interfere with daily tasks. Amyloid plaques are also found in the brain of Alzheimer patients. Neurocognitive effects associated with therapeutic drugs and animal cognition and behaviour - Fear and aversive learning and memory.

Related Conferences: 5th International Conference on Alzheimer’s Disease & Dementia, September 29-October 01, 2016, UK; 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5thWorld Congress on Neurology and Therapeutics, March 14-16 2016, UK; European Neurology Congress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia;Alzheimer’s Association International Conference, July 22-28 2016, Canada; Stress And Behavior Neuroscienceand Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna;Schizophrenia International Research Society Conference, April 2-6 2016, Italy

Track 11: Parkinson’s Disease

It is a progressive and chronic disorder, caused by death or malfunctioning of neurons, genetic mutation leading to decreased level of dopamine secretion. Associated effects are anxiety; depression, stress, ageing and neurodegenerative disorders, disease diagnostics, drug designing and therapeutics are the research areas.

Related Conferences:  2nd International Conference on Parkinson’s Disease & Movement Disorders November 28-30 2016, USA; 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5th World Congress on Neurology and Therapeutics, March 14-16 2016, UK; European Neurology Congress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Alzheimer’sAssociation International Conference, July 22-28 2016, Canada; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna;Schizophrenia International Research Society Conference, April 2-6 2016, Italy.

Track 12: Neuroethics

It includes the social, legal and ethical consequences of advances in neuroscience. It is the amalgamation of neuroscience with ethical thoughts. The ethics of neurocognitive includes brain interventions and imagining, neurological treatments and consciousness disorders. 

Related Conferences: 3rd World Congress on Pharmacology, August 08-10 2016, UK; 2nd International Conference on Epilepsy & Treatment, October 24-26 2016, Italy; 5th World Congress on Neurology andTherapeutics, March 14-16 2016, UK; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09 2016, Spain; European Neurology Congress September 10-12 2016, Amsterdam; Society for Neuroscience Annual Meeting,  November 12-16 2016, USA; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016,  Europe; AAPS Annual Meeting, November 13-17 2016, USA; Schizophrenia International Research Society Conference, April 2-6 2016, Italy; 47th Annual Autism Society National Conference, July 13-16 2016, USA

Track 13: Future Aspects of Neuropharmacology

Neuropharmacology is an emerging field of science, rising exponentially with the understanding of nervous system and its related disorders, drugs and treatments. The major area of research includes mechanisms of novel drugs, neuro stem cell therapy, immunoglobulin therapy, gene therapy in neuronal disorders and neural engineering. 

Related Conferences:  2nd International Conference on Parkinson's Disease & Movement Disorders November 28-30 2016, USA; 5th International Conference on Alzheimer’s Disease & Dementia, September 29-October 01, 2016, UK; 5th World Congress on Neurology and Therapeutics, March 14-16 2016, UK; European NeurologyCongress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Alzheimer’s Association International Conference, July 22-28 2016, Canada; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016, Europe; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna; Schizophrenia International Research Society Conference, April 2-6 2016, Italy.

Track 14: Case Study Reports

Case studies are an extremely useful records of the clinical practices of a profession. They are a record of clinical interactions which help us to frame questions for more rigorously designed clinical studies. Case studies also provide valuable teaching material, demonstrating both classical and unusual presentations which may challenge the practitioner.

Related Conferences:  2nd International Conference on Parkinson's Disease & Movement Disorders November 28-30 2016, USA; 5th International Conference on Alzheimer’s Disease & Dementia, September 29-October 01, 2016, UK; 5th World Congress on Neurology and Therapeutics, March 14-16 2016, UK; European Neurology Congress September 10-12 2016, Amsterdam; International Conference on Neuro-Oncology, July 21-23 2016, Australia; Alzheimer’s Association International Conference, July 22-28 2016, Canada; Stress And Behavior Neuroscience and Biopsychiatry Conference, May 16-19 2016, Russia; FENS Forum of Neuroscience, July 2-6 2016, Europe; ECNP 2016, 29th European College of Neuropsychopharmacology Congress, September 17-20 2016, Vienna; Schizophrenia International Research Society Conference, April 2-6 2016, Italy.

Track 15: Entrepreneurs Investment Meet

A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.